Subsequent Events (Details) - Subsequent Event - Licensing agreements for development and commercialization $ in Millions	1 Months Ended
	May 03, 2018 USD ($)
Pharmbio Korea Inc
Subsequent Events
Upfront payment	$ 3.0
Pharmbio Korea Inc | Maximum
Subsequent Events
Royalties on product sales, percentage	20.00%
Jiangsu Nhwa Pharmaceutical Co Ltd | United States And China
Subsequent Events
Upfront payment	$ 2.5
Milestone payment	$ 3.0
Jiangsu Nhwa Pharmaceutical Co Ltd | China
Subsequent Events
Royalties on product sales, percentage	10.00%
Jiangsu Nhwa Pharmaceutical Co Ltd | China | Maximum
Subsequent Events
Milestone payment	$ 6.0